BC
NVO

Barnett & Company’s Novo Nordisk NVO Stock Holding History

Barnett & Company’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,284
Closed -$39K – 339
2020
Q1 		$39K Sell
1,284
-114
-8% -$3.39K 0.04% 145
2019
Q4 		$40K Buy
1,398
+1,284
+1,126% +$35.6K 0.02% 183
2019
Q3 		$3K Buy
+114
New +$2.88K ﹤0.01% 296

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Barnett & Company's NVO Position: Q2 2020 in Review

Barnett & Company sold out of Novo Nordisk (NVO) in Q2 2020, closing a stake of 1,284 shares — an estimated $39K sold.

Barnett & Company first reported a position in NVO in Q3 2019 and held it in 3 quarters. The position peaked at $40K in Q4 2019. 660 funds tracked by Wall St. Rank hold NVO as of Q2 2020.

  • Barnett & Company reported no remaining Novo Nordisk position as of Q2 2020 after selling out during the quarter.
  • Barnett & Company sold 1,284 Novo Nordisk shares in Q2 2020, an estimated $39K.
  • Barnett & Company first reported a position in Novo Nordisk in Q3 2019 and held it in 3 quarters.
  • Barnett & Company's Novo Nordisk position peaked at $40K in Q4 2019.
  • 660 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2020.

Based on Barnett & Company's 13F filing for Q2 2020, filed 22 Jul 2020.